TICKERNERD
Menu
ADCTADCTHealthcare · Drug Manufacturers - Specialty & Generic

ADCT Stock Forecast: ADC Therapeutics SA Price Predictions for 2026-2027

Last close, 28 Oct 2026
$1.62
+1.89% on the day

The 5 Wall Street analysts covering ADC Therapeutics SA hold a median 12-month price target of $3 — +85.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$203.0M
Ticker Nerd rank
81/ 100
Median analyst target
$3.00
Analysts covering
5
Revenue$19.2M+2.2% y/y
Operating income−$22.8M
Net income−$16.6M
Free cash flow−$11.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.0%
1M
+28.6%
YTD
−54.1%
1Y
−63.4%
From 52W high
−66.8%
From 52W low
+68.8%
$0.96
$4.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ADC Therapeutics SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
81/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
91
Revisions
77
Issuance
76
Quality
71
Accruals
67
Size
67
Value
64
Volatility
21
Momentum
12

Growth (91): Sales and profits are climbing, and climbing faster than before.

Momentum (12): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ADCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26ADCTHigh $5.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $2.00Median $3.00High $5.00

The green dot is the last close — the median target sits +85.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026GuggenheimMaintainsBuy$10 → $5.00
8 June 2026HC Wainwright & Co.DowngradeNeutral—
8 June 2026HC Wainwright & Co.DowngradeNeutral—
4 June 2026RBC CapitalDowngradeSector Perform—
4 June 2026RBC CapitalDowngradeSector Perform$6.00 → $2.00
5 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026RBC CapitalReiteratesOutperform—
23 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Oct 2025HC Wainwright & Co.MaintainsBuy—
13 Aug 2025GuggenheimReiteratesBuy—
20 June 2025RBC CapitalMaintainsOutperform—
13 June 2025GuggenheimMaintainsBuy—
15 May 2025RBC CapitalReiteratesOutperform—
31 Mar 2025GuggenheimMaintainsBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025Cantor FitzgeraldReiteratesOverweight—
24 Feb 2025Stephens & Co.MaintainsOverweight—
6 Jan 2025HC Wainwright & Co.ReiteratesBuy—
12 Dec 2024GuggenheimReiteratesBuy—
11 Dec 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ADCT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ADCT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, ADC Therapeutics SA returned −63.4% against +13.6% for the S&P 500, dividends included.

ADCT vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26ADCTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

ADC Therapeutics SA (ADCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 84% of US stocks

Price / sales
2.5×

Cheaper than 47% of US stocks

Price / book
−1.1×

Cheaper than 95% of US stocks

EV / EBITDA
−4.5×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
2.2%

Higher than 33% of US stocks

Earnings growth (YoY)
2.2%

Higher than 39% of US stocks

Gross margin
87.8%

Higher than 95% of US stocks

Operating margin
−118.1%

Higher than 13% of US stocks

Net margin
−121.8%

Higher than 5% of US stocks

Returns & dividend
Return on equity
76.7%

Higher than 95% of US stocks

Return on assets
−19.6%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ADC Therapeutics SA (ADCT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ADC Therapeutics SA has a market value of $203.0M and an enterprise value of $422.1M.

  • Revenue in the twelve months to 30 June 2026: $79.6M. The latest quarter grew 2.2% year on year.

  • Net income over the same four quarters: −$96.9M, a −121.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.66.

  • Free cash flow in the twelve months to 30 June 2026: −$102.3M.

  • Shares outstanding: 127.4M.

  • Trailing P/E: −1.4×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ADC Therapeutics SA employs 188 people — $423K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

ADCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ADCTADC Therapeutics SA$203.0M81
AKBAAkebia Therapeutics, Inc.$176.9M76
SIGASIGA Technologies, Inc.$229.3M45
BIOABioAge Labs, Inc.$242.8M40
LFCRLifecore Biomedical, Inc.$244.1M3
CRDLCardiol Therapeutics, Inc.$149.2M—
OGIOrganigram Global, Inc.$136.1M—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ADC Therapeutics SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADCT news & analysis

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

PRNewsWire · 8 Oct 2026positive

ADC Therapeutics announced a financial restructuring that includes a $86.6 million private placement, an amended HealthCare Royalty agreement removing a change-of-control payment, and refinancing its senior secured loan with principal reduced to $50 million. The company said the measures are expected to extend its cash runway into 2029.

Why it matters — The financing and debt changes affect ADCT’s capital structure, liquidity terms, and expected cash runway.

These beaten-down stocks could bounce back in January, if history is any guide

Market Watch · 21 Sept 2026positive

Market Watch reported that tax-loss selling is likely to leave 20 stocks artificially depressed in the fourth quarter, making them candidates to bounce back in January. The report suggests history points to a rebound for these beaten-down stocks in the new year.

Why it matters — For ADCT watchers, the report indicates that if ADC Therapeutics is among these stocks, its recent weakness may be driven by tax-loss selling and could reverse in January.

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

PRNewsWire · 3 Sept 2026neutral

ADC Therapeutics SA announced that its Chief Executive Officer, Ameet Mallik, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 11, 2026, at 9:10 a.m.

Why it matters — A fireside chat at a major healthcare conference gives investors an opportunity to hear directly from ADCT leadership about the company's outlook.

ADC Therapeutics Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026neutral

ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, with management saying the treatment's commercial performance remained broadly consistent with recent quarters during the Q2 earnings call.

Why it matters — The quarter-over-quarter growth and management's assessment of ZYNLONTA's commercial performance provide a point of reference for investors tracking ADC Therapeutics' revenue trajectory.

ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

ADC Therapeutics SA held its Q2 2026 earnings call, with the transcript published by Seeking Alpha. The call covered the company's financial results and operational updates for the quarter.

Why it matters — Earnings calls provide ADCT watchers with direct management commentary on the company's financial performance and strategic direction.

FAQ

Frequently asked questions about ADCT stock

What is the ADCT stock price forecast for 2026-2027?

The 5 Wall Street analysts covering ADC Therapeutics SA have a median 12-month price target of $3, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADCT stock a buy right now?

Of the 5 analysts covering ADC Therapeutics SA, 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ADC Therapeutics SA 81 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADCT?

As at 27 Oct 2026, ADC Therapeutics SA ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).

Will ADCT stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +85.2% from the last close, and Ticker Nerd's factor model ranks ADC Therapeutics SA 81 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADCT stock forecast for 2030?

No analyst covering ADC Therapeutics SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has ADCT stock performed over the past year?

ADC Therapeutics SA returned -63.4% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ADC Therapeutics SA do?

ADC Therapeutics SA is a Switzerland-based biotechnology company focused on developing and commercializing targeted antibody-drug conjugates for cancer treatment. Its portfolio centers on oncology programs designed to address hematological malignancies and solid tumors, with a particular emphasis on precision therapies that link monoclonal antibodies to potent cytotoxic agents.

What is the latest news on ADCT?

The most recent item we track (PRNewsWire, 8 Oct 2026): "ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements". ADC Therapeutics announced a financial restructuring that includes a $86.6 million private placement, an amended HealthCare Royalty agreement removing a change-of-control payment, and refinancing its senior secured loan with principal reduced to $50 million. The company said the measures are expected to extend its cash runway into 2029.

Company

About ADC Therapeutics SA.

ADC Therapeutics SA is a Switzerland-based biotechnology company focused on developing and commercializing targeted antibody-drug conjugates for cancer treatment. Its portfolio centers on oncology programs designed to address hematological malignancies and solid tumors, with a particular emphasis on precision therapies that link monoclonal antibodies to potent cytotoxic agents. The company’s current products and pipeline include ZYNLONTA and several investigational candidates such as loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. ADC Therapeutics SA operates in the specialty biopharmaceutical market, where antibody-drug conjugates are used to improve tumor targeting and expand treatment options for difficult-to-treat cancers. Headquartered in Epalinges, Switzerland, the company serves a global healthcare setting through research, development, and commercialization activities centered on next-generation oncology medicines.

CEO Dr. Ameet Mallik M.B.A., M.S. · 188 employees · Switzerland · https://www.adctherapeutics.com